FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences.
2024 ThinkEquity ConferenceDate: October 30, 2024Location: New York, NYFormat: Company PresentationTime: 10:30 a.m. ET
BIO-Europe 2024Date: November 5, 2024Location: Stockholm, SwedenFormat: Company PresentationTime: 1:30 p.m. CET
For more information, please visit FibroBiologics'websiteor email FibroBiologics at:info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visitwww.FibroBiologics.com.
General Inquiries:info@fibrobiologics.com
Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com
Released October 28, 2024